Women living with HIV and dual contraceptive use in Ethiopia: systematic review and meta-analysis

Asteray Ayenew*

Abstract

Background: Despite different preventive strategies that have been implemented in the country, the prevalence of HIV/AIDS is still significantly increasing in Ethiopia. The concurrence of HIV and unintended pregnancy makes the use of dual contraception a backbone for the simultaneous protection against HIV, and unintended pregnancy. As a result, this systematic review and meta-analysis aimed to assess the prevalence and associated factors of dual contraceptive use among women living with HIV in Ethiopia.

Method: We used databases; (PubMed, Google Scholar, EMBASE, Cochrane Library, African Online Journals, and Hinary), other gray and online repository accessed studies were searched using different search engines. For critical appraisal of studies Newcastle-Ottawa Quality Assessment Scale (NOS) was used. The analysis was done using STATA 11 software. The Cochran Q test and I² test statistics were used to assess the heterogeneity. To detect publication bias funnel plot and Egger’s test were used. The pooled prevalence of dual contraception use and the odds ratio (OR) with a 95% confidence interval was presented by using forest plots.

Result: Eleven studies were included in this review, with a total of 4083 women living with HIV in Ethiopia. The pooled prevalence of dual contraception use in Ethiopia was 34.08% (95%CI: 20.77–47.38). Having open partner discussion (OR = 3.96, 95%CI:2.3,6.8), provision of post test counseling (AOR = 4.38, 95%CI:2.93,6.54), disclosed HIV status to sexual partners (OR = 5.9, 95%CI:4.19,8.33), partner involvement in post-test counseling (OR = 3.52, 95%CI:2.37,5.23), and being on highly active antiretroviral therapy (HAART) (OR = 2.9, 95%CI:1.56,5.46) were the determinant factors of dual contraceptive use in Ethiopia.

Conclusion: The overall prevalence of dual contraceptive use among women living with HIV in Ethiopia was low. Having open partner discussion, provision of post-test counseling, disclosed HIV status to sexual partner, partner involvement in post-test counseling, and currently on highly active antiretroviral therapy (HAART) were the associated factors of dual contraceptive use. Therefore, efforts should be made to provide post-test counseling, and initiate partner involvement in post-test counseling. Moreover, promoting open partner discussion, counseling to disclose HIV status to their sexual partner and to start HAART will be helpful in enhancing the use of dual contraceptive method use.

Keywords: Dual contraceptive use, Women living with HIV, Systematic review and meta-analysis, Ethiopia
Saharan Africa where, 60% of people reported to live with human immune deficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and more than half of them were females [2]. The total number of people living with HIV in Ethiopia was 769,600 in 2014. Of these females cover more than 60% [3].

HIV/AIDS continues to have disastrous medical, social, economic, and physical impacts on individuals, nations and the global community at large [4]. Unintended pregnancies accounted for 21.3% of new pediatric HIV infections, and 90% were from Sub Saharan Africa [5, 6]. In Ethiopia, annually, over 100,000 pregnancies tested positive for HIV and over 12,000 HIV-positive births. Unintended pregnancies contribute to poor maternal and child outcomes especially among HIV infected women [7, 8].

Dual protection can be achieved through the use of barrier method (condoms) or dual method (condoms + another modern contraceptive method) use [9]. Dual contraception can be an effective strategy to prevent HIV transmission to partners, prevalence of mother to child transmission, and to prevent unintended pregnancy. Evidence show that 40 and 80% of unplanned pregnancies and abortions would be prevented if half and all of them who were using one type of contraceptive alone started using dual methods [10]. Additionally, an interventional based study had also demonstrated that adherence to the dual contraception lower the rate of unintended pregnancy at 24 months [11].

Currently, in Ethiopia, HIV transmission is very high and is a major public health problem. Due to low dual contraceptive method use, many HIV positive women are still facing unintended pregnancy, and its complication with a concomitant risk of mother to child transmission (MTCT) of HIV, pregnancy related morbidity and mortality. The national health policy of Ethiopia recommends the use of dual contraception as a key intervention to reduce transmission of HIV/AIDS, PMTCT, and unintended pregnancy. Additionally, the Ministry of health in collaboration with partners developed the post 2015 objective of prevention of mother-to-child transmission (PMTCT) to consolidate & sustain the elimination of MTCT and reduce the vertical transmissions to less than 2% by 2020. To ensure virtual elimination, one of the main focuses is improving the use of dual protection among HIV positive women by integrating family planning services with PMTCT [12]. As a result, this systematic review
and meta-analysis aimed to estimate the pooled prevalence of dual contraception use among women living with HIV and its associated factors in Ethiopia.

**Methods**
This systematic review and meta-analysis were conducted to estimate the national use of dual contraception and its associated factors among women living with HIV in Ethiopia. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist guideline [13].

**Searching strategy**
First, the PROSPERO database and database of abstracts of reviews of effects (DARE) (http://www.library.UCSF.edu) were searched to check whether published or ongoing projects exist related to the topic. The literature search strategy, selection of studies, data extraction, and result reporting were done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14]. We searched PubMed, Google Scholar, EMBASE, Cochrane Library, HINARI, WHO Afro Library Databases, and African Online Journal databases for all available studies using the following terms: “dual contraception use” OR “dual protection” OR “condom” AND “sexually active women living with HIV” OR “condom” OR “modern contraception” OR “use of dual methods” OR “prevalence” OR “determinants” AND “Ethiopia”. The search string was developed using “AND” and “OR” Boolean operators. Searching terms were based on adapted PICO principles to search through the above-listed databases to access all the relevant articles. For unpublished studies, the official websites of Ethiopian’s University research repository online library (University of Gondar and Addis Ababa University) was used.

**Inclusion and exclusion criteria**
Studies reported the prevalence and/or associated factors, or determinant factors of dual contraception method use were included in this study. English language literature and research articles only were included. Whereas articles without full text and abstract, anonymous reports, duplicate studies and editorial reports were excluded.

**Data extraction and quality assessment**
After collecting the findings from all databases, the articles were exported to Microsoft Excel spreadsheet. Newcastle-Ottawa Quality Assessment Scale (NOS) for cross-sectional was used to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis [15]. All the included articles scored (NOS) 7 and more can be considered as “good” studies with low risk.

**Statistical analysis**
As the test statistic showed significant heterogeneity among studies ($I^2 = 99.4\%, p < 0.05$) the Random-effects model was used to estimate the DerSimonian and Laird’s pooled effect [16]. Cochran’s Q chi-square statistics and $I^2$ statistical test was conducted to assess the random variations between primary studies [17]. In this study, heterogeneity was interpreted as an $I^2$ value of 25% = low, 50% = moderate, and 75% = high [18]. In case of high heterogeneity, subgroup analysis and sensitivity analyses were run to identify possible moderators of this

**Table 1** Descriptive summary of included studies on dual contraceptive method utilization

| Author (year of study)          | Study area                                    | Sample size | Study region | Prevalence (%) |
|--------------------------------|-----------------------------------------------|-------------|--------------|----------------|
| Mebratu M.et al.(2018) [20]    | University of Gondar hospital                 | 376         | Amhara       | 13.2           |
| Solomon wet al.(2016) [21]     | public hospitals of Northern Ethiopia         | 331         | Tigray       | 23             |
| Markos S.et al.(2019) [22]     | Art Clinics in West Zone Health Facilities Oromia, Ethiopia | 323         | Oromia       | 25             |
| Dereje B.et al.(2015) [23]     | Gebretsadik Shawo Hospital, SNNPR, South West Ethiopia | 246         | SNNPR        | 19.8           |
| Meseret W. et al.(2015) [22]   | Gondar City, northwest, Ethiopia:             | 655         | Amhara       | 30             |
| Fewuze A.et al. ABAY(2018) [23]| Tigray Region, Northern Ethiopia              | 964         | Tigray       | 14.3           |
| Melaku Y.et al.(2014) [3]      | Hosanna Hospital, Southern Ethiopia;           | 403         | Amhara       | 30.9           |
| Addisu P. et al. [24]         | ART attendees in health facilities of Gimbie town, West Ethiopia | 424         | Oromia       | 30             |
| Yemane B. et al. [25]          | HIV Positive Reproductive Age Women in Tigray | 364         | Tigray       | 59.9           |
| Assefa A. et al. [26]          | HIV Positive Women in Reproductive Age Group, Region, Northwest Ethiopia | 409         | Amhara       | 40.9           |
| Alemu T. et al. [27]           | HIV Positive Women in Reproductive Age Group, Oromia Region | 348         | Oromia       | 85.2           |
heterogeneity. Potential publication bias was assessed by visually inspecting funnel plots and objectively using the Egger's test (i.e., $p < 0.05$) [19]. To account for any publication bias, we used the trim-and-fill method, based on the assumption that the effect sizes of all the studies are normally distributed around the center of a funnel plot. The meta-analysis was performed using the Stata version 11.0 (Stata Corporation, College Station, Texas, USA) software. Finally, for all analyses, $P < 0.05$ was considered statistically significant.

Results

Study selection and data extraction

The search strategy identified 80 articles from PubMed, 60 articles from Google Scholar, 45 articles from Cochrane Library, 10 articles from African Journals Online, 7 articles from Ethiopian’s University online library, and 5 articles by manual search. Of which, 134 were excluded due to duplication, 35 through review of titles and abstracts. Additionally, 31 full-text articles were excluded for not reporting the outcome variable and other reasons. Finally, 11 were included to the prevalence and/or associated factor analysis on dual contraception use (Fig. 1).

| Study ID | ES (95% CI) | Weight |
|----------|-------------|--------|
| Mebratu M. et al | 13.20 (9.78, 16.62) | 9.12 |
| Solomon W. et al | 15.70 (11.78, 19.62) | 9.11 |
| Markos S. et al | 19.16 (14.46, 23.86) | 9.08 |
| Deneje B. et al | 32.00 (27.16, 36.84) | 9.07 |
| Meselet W. et al | 29.80 (24.08, 35.52) | 9.03 |
| Fewuze A. et al ABAY | 28.80 (25.06, 32.54) | 9.11 |
| Melaku Y. et al | 20.30 (17.76, 22.84) | 9.15 |
| Addisu P. et al | 30.00 (25.64, 34.36) | 9.09 |
| Yemane B. et al | 59.90 (54.67, 64.93) | 9.06 |
| Alemu T. et al | 85.20 (81.47, 88.93) | 9.11 |
| Assessa A. et al | 40.90 (36.10, 45.70) | 9.07 |
| Overall (I-squared = 99.2%, $p = 0.000$) | 34.98 (20.77, 47.38) | 100.00 |

NOTE: Weights are from random effects analysis

Fig. 2 Forest Plot for the Prevalence of dual contraception use among women living with HIV in Ethiopia
Prevalence of dual contraceptive use among women living with HIV
A wide-ranging prevalence of dual contraceptive use was observed across different studies included in this review. The overall pooled prevalence of dual contraceptive use among women living with HIV in Ethiopia was 34.08% (95%CI: 20.77–47.38, $I^2 = 99.2\%$, $p = <0.001$) (Fig. 2).

Subgroup analysis
Subgroup analysis was employed with the evidence of heterogeneity. In this study, the Cochrane $I^2$ statistic was 99.2%, $P < 0.001$, which showed the evidence of marked heterogeneity. Therefore, subgroup analysis was done using the study region and year of study. As a result, dual contraception use among women living with HIV was highest in Oromia region 49.09%, whereas 43.58% in the study conducted between 2015 and 2017 (Figs. 3 and 4).

Publication bias
The funnel plot was assessed for asymmetry distribution of prevalence of dual contraception use among women’s living with HIV by visual inspection (Fig. 5). Egger’s regression test showed a $p$-value of 0.436 with no evidence of publication bias.

Sensitivity analysis
This systematic review and meta-analysis showed that the point estimate of its omitted analysis lies within the confidence interval of the combined analysis. Therefore, trim and fill Analysis was no further computed (Fig. 6).

Determinants of dual contraception use among women living with HIV
The association between having open partner discussion, provision of post test counseling, disclosed HIV status to sexual partner, partner involvement in post-test
counseling, and currently on highly active antiretroviral therapy (HAART) with dual contraception use was carried out.

Six studies were included in this category of meta-analysis [3, 20–23] to associate open partner discussion with dual contraception use. Women who discuss openly with sexual partner about dual contraception method were 3.96 times (AOR: 3.96, 95% CI: 2.3–6.8) more likely to use dual contraception as compared to those women who did not have open discussion with sexual partner (Fig. 7).

Five studies were included in this category of meta-analysis [3, 20–23]. The odds of using dual protection among women living with HIV who counseled during post-test was 4.38 times (AOR: 4.38, 95% CI: 2.93–6.54) more compared with their counterparts (Fig. 8).

Four studies were included in this category of meta-analysis [20, 21, 23, 24]. HIV-positive women who disclosed their HIV status to sexual partners were 5.91 times (AOR: 5.91, 95% CI: 4.19–8.33) more likely to use dual contraception as compared to those who did not disclose their status to sexual partner (Fig. 9).

Tree studies were included in this category of meta-analysis [21–23]. The odd of using dual contraception among women of living with HIV with currently on HAART was 2.92 times (AOR= 2.92, 95% CI: 1.56–5.46) more likely compared with their counterparts (Fig. 10).

Four studies were included in this category of meta-analysis [3, 20, 23, 24]. The likelihood of using dual contraception among women living with HIV whose partners involved in post test counseling were 3.52 times (AOR=3.52, 95% CI: 2.3–5.3) more likely to use dual contraception than women whose partners did not involved in post test counseling (Fig. 11).

| Author              | ES (95% CI) | %   |
|---------------------|------------|-----|
| 2018-2019           |            |     |
| Mebratu M.et al     | 13.20 (9.78, 16.62) | 9.12 |
| Markos S. et al     | 19.16 (14.46, 23.86) | 9.08 |
| Fewuze A. et al ABAY| 28.80 (25.06, 32.54) | 9.11 |
| Assefa A. et al     | 40.90 (36.10, 45.70) | 9.07 |
| Subtotal (I-squared = 96.9%, p = 0.000) | 25.46 (13.86, 37.06) | 36.38 |
| 2015-2017           |            |     |
| Solomon W. et al    | 15.70 (11.78, 19.62) | 9.11 |
| Mersen W. et al     | 29.80 (24.08, 35.52) | 9.03 |
| Alemu T. et al      | 85.20 (81.47, 88.93) | 9.11 |
| Subtotal (I-squared = 99.7%, p = 0.000) | 43.58 (-2.76, 89.92) | 27.25 |
| 2012-2014           |            |     |
| Dereje B. et al     | 32.00 (27.16, 36.84) | 9.07 |
| Melaku Y. et al     | 20.30 (17.76, 22.84) | 9.15 |
| Addisu P. et al     | 30.00 (25.64, 34.36) | 9.09 |
| Yemane B. et al     | 59.90 (54.87, 64.93) | 9.06 |
| Subtotal (I-squared = 98.4%, p = 0.000) | 35.47 (19.39, 51.55) | 36.37 |
| Overall (I-squared = 99.2%, p = 0.000) | 34.08 (20.77, 47.38) | 100.00 |

NOTE: Weights are from random effects analysis

Fig. 4 Subgroup analysis of the pooled prevalence of dual contraception use among women living with HIV based on year of study.
Discussion

According to the results of this meta-analysis, the pooled prevalence of dual contraception use in Ethiopia was estimated to be 34.08% (95%CI: 20.77–47.38). This finding was lower than the studies done in Kenya [28], Tanzania [29], United States of America [30], and systematic review done by Marge Berer [9]. The high dual contraception prevalence in Kenya and Tanzania might be as a result of campaigns to scale-up dual protection use by involving service providers and change in
Fig. 7 Forest plot displaying the relationship between open partner discussion and dual protection use in Ethiopia

| Study ID | ES (95% CI)     | Weight |
|---------|-----------------|--------|
| Mebratu M. et al | 4.26 (2.32, 7.82) | 17.65 |
| Solomon W. et al | 2.75 (1.12, 6.77) | 13.93 |
| Markos S. et al | 7.49 (5.06, 11.88) | 20.28 |
| Dereje B. et al | 1.20 (0.54, 2.68) | 15.13 |
| Meselet W. et al | 8.20 (3.82, 17.61) | 15.62 |
| Melaku Y. et al | 3.42 (1.83, 6.40) | 17.39 |
| Overall (I-squared = 76.2%, p = 0.001) | 3.96 (2.30, 6.80) | 100.00 |

NOTE: Weights are from random effects analysis

Fig. 8 Forest plot displaying the association between provision of post-test counseling and dual contraception use in Ethiopia

| Study ID | ES (95% CI)     | Weight |
|---------|-----------------|--------|
| Mebratu M. et al | 6.55 (3.43, 12.51) | 19.60 |
| Solomon W. et al | 3.03 (1.36, 6.78) | 15.35 |
| Markos S. et al | 5.99 (4.83, 7.43) | 35.76 |
| Dereje B. et al | 3.16 (1.12, 8.92) | 10.87 |
| Melaku Y. et al | 2.56 (1.29, 5.08) | 18.43 |
| Overall (I-squared = 54.4%, p = 0.067) | 4.38 (2.93, 6.54) | 100.00 |

NOTE: Weights are from random effects analysis
dual-protection counseling. The high use in USA could be due to the high quality and strong integration of Sexual Reproductive Health (SRH) services with services of HIV [31].

Women who ever had open discussion with sexual partner about dual protection were 3.96 times more likely to use dual protection as compared to women who were not. This result is supported by a study conducted...
Tanzania [32]. This can be explained by the fact that women who openly discuss using dual protection with sexual partner could better understand the importance of dual protection. Additionally, open discussion on using dual protection with sexual partner would give confidence and freedom for both choosing the appropriate contraceptive methods and freedom to negotiate safer sex and birth spacing.

 Provision of post-test counseling by health care provider was significant factor to use dual protection among HIV positive women. Those counseled by health care provider to use dual protection after tested positive were 4.3 more odds of using dual contraception. This agrees with a study conducted in Zambia [33], India [34], Tanzania [32], and Kenya [35]. This strongly indicates that counseling of HIV positive women can improve the utilization of dual contraceptive use in preventing sexually transmitted infections and unintended pregnancy. It also indicates that health care providers need to focus on counseling on dual contraception and its benefit to HIV positive women during post-test counseling and during follow up at the ART clinic.

 Disclosing HIV status to sexual partners showed statistically significant association with dual contraceptive use among women living with HIV. Women who disclosed HIV status to sexual partner were nearly 5.9 times more likely to utilize dual contraception as compared to those women who did not disclose their status to sexual partners. Similar study findings were observed in different countries: Kenya [36], India [37], and Zambia [33]. It could be due to the fact that disclosure likely facilitates open discussion between partners in relation to HIV infection, dual contraception, and both parties might understand the importance of consistent dual contraceptive use. Moreover, women who disclose their status to their sexual partner might be supported each other and promote to visit health care facilities for counseling which in turn promote dual contraceptive use.

 The odds of dual contraceptive use among women with partner’s involvement in post-test counseling were about 3.52 times higher than their counterparts. The finding of this study is consistent with the study done in India [34]. This possible reason might be testing and counseling sexual partners together encourages them to have open discussion while choosing the appropriate contraceptive methods they use.

 This review also showed that being currently on highly active antiretroviral therapy (HAART) was significantly associated with dual protection use among women living with HIV. Women who were on (HAART) were nearly 3 times more likely to use dual contraception as compared to their counter parts. This result is supported by study done in Brazil [38]. The possible reason might be being on HAART requires frequent visits to healthcare facilities which may be linked to greater exposure to safe sex counseling, dual protection, greater access to condoms, and health care seeking behavior. Moreover, women who care for
themselves by adhering to HAART regimens may have greater odds of also protecting their sexual partners by using condoms consistently.

Limitations
This meta-analysis was included only articles conducted in the English language, which may have restricted some papers conducted in local language from being included. Additionally, all the included articles were cross-sectional; as a result, the outcome variables might be affected by confounding variables and it might be difficult to address the temporal cause and effect relationship via cross-sectional studies.

Conclusion
The pooled prevalence of dual contraceptive was low among women living HIV was low in Ethiopia. Having open partner discussion, provision of post-test counseling, disclosed HIV status to sexual partner, partner involvement in post-test counseling, and currently on highly active antiretroviral therapy (HAART) were the determinants factors of dual contraceptive in Ethiopia. Therefore, efforts might be made to improve the use of dual contraception by providing simultaneous HIV testing and counseling of women with their partner, promoting open partner discussion, and provision of counseling by health care providers during post testing, and follow up at the ART clinics regarding dual contraception shall be encouraged.

References
1. UNAIDS. Global HIV statistics. In: Fact sheet 2018; 2017.
2. UNAIDS, A. Epidemic update in united nations joint programme on HIV/ AIDS. Geneva: WHO/UNAIDS, 2011.
3. Melaku YA, Zeleke EG. Contraceptive utilization and associated factors among HIV positive women on chronic follow up care in Tigray region, northern Ethiopia: a cross sectional study. PLoS One. 2014;9(6):e94682.
4. WHO, U. Global summary of AIDS epidemic report. Geneva: WHO; 2007. p. 2–5.
5. USAID. The gap report children and pregnant women living with HIV. 2015.
6. WHO. WHO, global update on the health sector response to HIV. 2014.
7. Reynolds HW, et al. Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries. Sex Transm Infect. 2008;84(Suppl 2):i49–53.
8. Lawani LO, Onyebuchi AK, Iyoke CA. Dual method use for protection of pregnancy and disease prevention among HIV-infected women in south East Nigeria. BMC Womens Health. 2014;14(1):39.
9. Berer M. Dual protection: more needed than practised or understood. Reprod Health Matters. 2006;14(28):162–70.
10. Pazol K, Kramer MR, Hogue CJ. Condoms for dual protection: patterns of use with highly effective contraceptive methods. Public Health Rep. 2010;125(2):208–17.
11. Peipert JF, et al. Tailored intervention to increase dual-contraceptive method use: a randomized trial to reduce unintended pregnancies and sexually transmitted infections. Am J Obstet Gynecol. 2008;198(6).360.e1–8.
12. office, F.H.A.p.a.c. The Federal Democratic Republic of Ethiopia, Ministry of Health. HIV/AIDS strategic plan 2015–2020 in an investment case approach. Addis Ababa: Ministry of Health Ethiopia; 2014.14.
13. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Public Lib Sci Med. 2009;6(6):e1000097.
14. Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
15. Downs MJ, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
17. Huedo-Medina TB, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.
18. Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions, Cochrane book series; 2008. p. 187–241.
19. Altman DG. “Systematic reviews of evaluations of prognostic variables.” BMJ (Clinical research ed) 2001;323(7306):224–8. https://doi.org/10.1136/bmj.323.7306.224.
20. Retal MM, Tessema GA, Shiferaw G. Prevalence of dual contraceptive use and associated factors among HIV positive women at University of Gondar Hospital, Northwest Ethiopia. BMC Res Notes. 2019;12:36. https://doi.org/10.1186/s13104-019-4053-2.
21. Gebrehiwot SW, et al. Utilization of dual contraception method among reproductive age women on antiretroviral therapy in selected public hospitals of northern Ethiopia. Reprod Health. 2017;14(1):125.
22. Erashi MW, Tess FJ, Beyene TT. Dual-contraceptive method utilization and associated factors among HIV positive women attending art Clinic in Gebredesadik Shavo hospital, SNNPR, South West Ethiopia, 2015.
23. Abay F, Yeshita HY, Mekonnen FA, Sisay M. Dual contraception method utilization and associated factors among sexually active women on antiretroviral therapy in Gondar City, northwest Ethiopia: a cross

Consent for publication
Not applicable.

Competing interests
The author(s) has/have no financial and non-financial competing interests.

Received: 5 November 2020 Accepted: 2 June 2022 Published online: 02 July 2022

Abbreviations
AIDS: Acquired immune deficiency syndrome; ART: Antiretroviral therapy; CI: Confidence Interval; HAART: Highly active AIDS: Acquired immune deficiency syndrome; AOR: Adjusted Odds Ratio; Abbreviations

Acknowledgments
N/A

Author's contributions
The author(s) read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
The data sets generated during the current study are available from corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.
sectional study. BMC Womens Health. 2020;20(1):26. https://doi.org/10.1186/s12905-020-0890-3 PMID: 32050961; PMCID: PMC7017555.

24. Polisi A, et al. Modern contraceptive utilization among female ART attendees in health facilities of Gimbi town, West Ethiopia. Reprod Health. 2014;11:30.

25. Berhane Y, et al. Utilization of modern contraceptives among HIV positive reproductive age women in Tigray, Ethiopia: a cross sectional study. ISRN AIDS. 2013;2013:319724.

26. Alemayehu A, Akillul. Determinants of dual contraceptive use among HIV Positive women in reproductive age group, Benishangul Gumuz region, Northwest Ethiopia. Int J Multidiscip Res Stud. 2018;1(03):170–80.

27. Alemu T. Assessment of modern contraceptive utilization and associated factors among female anti-retroviral therapy attendants in Arada sub city, Addis Ababa, Ethiopia; 2016.

28. Mulongo AM, et al. Factors associated with uptake of dual contraception among HIV-infected women in Bungoma County, Kenya: a cross-sectional study. Pan Afr Med J. 2017;28(Suppl 1):2–2.

29. James Samwel Ngocho EK. Prevalence Of Modern Contraceptive Methods Use Among Women Living With HIV Attending Care And Treatment Clinic At Amana Hospital Dar Es Salaam, Tanzania. Int J Soc Sci Humanit Invent. 2015;2(12). Retrieved from https://valleyinternational.net/index.php/theisshi/article/view/295.

30. Sutton MY, Zhou W, Frazier EL. Unplanned pregnancies and contraceptive use among HIV-positive women in care. PLoS One. 2018;13(5):e0197216.

31. Wilson TE, et al. Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: the importance of an event-level focus for promoting safer sexual behaviors. Sex Transm Dis. 2003;30(11):809–12.

32. Chibwesha CJ, Li MS, Matoba CK, Mbewe RK, Chi BH, Stringer JSA, et al. Modern contraceptive and dual method use among HIV-infected women in Lusaka, Zambia. Infect Dis Obstet Gynecol. 2011;2011:8.

33. Chakrapani V, Kershaw T, Shunmugam M, Newman PA, Cornman DH, Dubrow R. Prevalence of and barriers to dual-contraceptive methods use among married men and women living with HIV in India. Infect Dis Obstet Gynecol. 2011;3:7.

34. Mulongo AM, Lihana RW, Githuku J, Gura Z, Karanja S. Factors associated with uptake of dual contraception among HIV-infected women in Bungoma County, Kenya: a cross-sectional study. Pan Afr Med J. 2017;10:11604.

35. Mulongo AM, Lihana RW, Githuku J, Gura Z, Karanja S. Factors associated with uptake of dual contraception among HIV-infected women in Bungoma County, Kenya: a cross-sectional study. Pan Afr Med J. 2017;28:Suppl 1:2. https://doi.org/10.11604/pamj.supp.2017.28.1.9289. PMID: 30167030; PMCID: PMC6113694.

36. Joshi B, Velhal G, Chauhan S, Kulkarni R, Begum S, Nandanvar YS, et al. Contraceptive use and unintended pregnancies among HIV-infected women in Mumbai. Indian J Community Med. 2015;40(3):168.

37. Tsuyuki K, Barbosa RM, de Araujo Pinho A. Dual protection and dual methods in women living with HIV: the Brazilian context. J Sex Transm Dis. 2013;36(7):S407-89.